Literature DB >> 15958072

Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.

H W Wang1, D Cole, W Z Jiang, H T Jin, N Fu, Z L Chen, N Y Jin.   

Abstract

The HIV-1 envelope glycoprotein surface subunit gp120 is an attractive target for molecular intervention. This is because anti-HIV-1 gp120 neutralizing antibodies display the potential ability to inhibit HIV-1 infection. The present investigation describes the construction of a genetically engineered single chain antibody (scFv102) against HIV-1 gp120, its expression and functional evaluation. The parental hybridoma cell line (102) produces an immunoglobulin directed against the conserved CD4-binding region of gp120. cDNAs encoding the variable regions of the heavy (V(H)) and light (V(L)) chains were prepared by reverse transcription PCR and linked together with an oligonucleotide encoding a linker peptide (Gly(4)Ser)(3) to produce a single chain antibody gene. The resulting DNA construct was cloned into a prokaryotic expression vector (pET28) and recombinant scFv102 was expressed in Eserichia coli as an insoluble protein. The denatured scFv102 was refolded and purified by immobilized metal ion affinity chromatography. Purified scFv102 had the same specificity as the intact IgG in immuno-blotting assays and immuno-fluorescence (IF) detection, but ELISA analyses demonstrated the affinity of scFv102 to be 5-fold lower than that of the parental monoclonal antibody. In neutralization assays, scFv102 at concentrations lower than 40 microg/ml exhibited efficient interference with viral replication and inhibition of viral infection (90%) across a range of primary isolates of subtype B HIV-1. These results suggest that the constructed anti-HIV-1 gp120 scFv102 has good biological activity and can potentially be used for in vitro diagnostic and in vivo therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958072      PMCID: PMC1809408          DOI: 10.1111/j.1365-2249.2005.02826.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  HIV gp120: double lock strategy foils host defences.

Authors:  Q J Sattentau
Journal:  Structure       Date:  1998-08-15       Impact factor: 5.006

2.  cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication.

Authors:  D Tewari; S L Goldstein; A L Notkins; P Zhou
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

Review 3.  Enhancing antibodies in HIV infection.

Authors:  G Füst
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

4.  Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay.

Authors:  R L Kline; D McNairn; M Holodniy; L Mole; D Margolis; W Blattner; T C Quinn
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

5.  Biologically active human anti-crotoxin scFv isolated from a semi-synthetic phage library.

Authors:  P Lafaye; V Choumet; C Demangel; C Bon; J C Mazié
Journal:  Immunotechnology       Date:  1997-06

6.  Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Authors:  Nicole M Haynes; Joseph A Trapani; Michèle W L Teng; Jacob T Jackson; Loretta Cerruti; Stephen M Jane; Michael H Kershaw; Mark J Smyth; Phillip K Darcy
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

7.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

Authors:  M C Gauduin; P W Parren; R Weir; C F Barbas; D R Burton; R A Koup
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

8.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

9.  Production of uninfectious human immunodeficiency virus type 1 containing viral protein R fused to a single-chain antibody against viral integrase.

Authors:  N Okui; N Kobayashi; Y Kitamura
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

View more
  3 in total

1.  Isolation of Specific Human Recombinant Antibodies Against Glycoprotein 41 of HIV.

Authors:  Mohammad Javad Aghaei Afshar; Reza Robati; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2019-10

2.  Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library.

Authors:  Vahid Bagheri; Foroogh Nejatollahi; Seyed Alireza Esmaeili; Amir Abbas Momtazi; Mohamad Motamedifar; Amirhossein Sahebkar
Journal:  Life Sci       Date:  2016-11-23       Impact factor: 5.037

3.  Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.

Authors:  Angela Marcobal; Xiaowen Liu; Wenlei Zhang; Antony S Dimitrov; Letong Jia; Peter P Lee; Timothy R Fouts; Thomas P Parks; Laurel A Lagenaur
Journal:  AIDS Res Hum Retroviruses       Date:  2016-04-13       Impact factor: 2.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.